Symbol of the Government of Canada

Canadian Patents Database

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.

Patent Summary

(12) Patent Application: (11) CA 2492434
(54) English Title: METHOD OF ENHANCING AND/OR INDUCING NEURONAL MIGRATION USING ERYTHROPOIETIN
(54) French Title: PROCEDE PERMETTANT D'ACCROITRE ET/OU D'INDUIRE UNE MIGRATION NEURONALE AU MOYEN DE L'ERYTHROPOIETINE

Representative Drawing

Sorry, the requested images are unavailable. Please try again in a few minutes and contact us  if the problem persists.

Abstracts

English Abstract




Methods are described for the enhancement and/or induction of migration of
neural stem cells or neuronal progenitor cells. Multipotent neural stem cells
are exposed to erythropoietin which enhances the migration of multipotent
neural stem cells and neuronal progenitor cells. The erythropoietin may be
exogenously applied to the multipotent neural stem cells, or alternatively,
the cells can be subjected to hypoxic insult which induces the cells to
express erythropoietin. In a preferred embodiment, additional growth factors,
such as EGF and prolactin, are utilized.


French Abstract

L'invention concerne des procédés permettant d'accroître et/ou d'induire une migration de cellules souches neurales ou de cellules progénitrices neuronales. Des cellules souches neurales multipotentes sont exposées à l'érythropoiétine accroissant la migration desdites cellules et des cellules progénitrices neuronales. L'érythropoiétine peut être appliquée de manière exogène sur les cellules souches neurales multipotentes ou, de manière alternative, les cellules peuvent être soumises à une agression hypoxique induisant l'expression de l'érythropoiétine par les cellules. Dans un mode de réalisation préféré, des facteurs de croissance supplémentaires, tels que le facteur de croissance de l'épiderme (EGF) et la prolactine, sont utilisés.



Patent Details

(51) International Patent Classification (IPC):
  • A61K 38/18 (2006.01)
  • A61K 38/22 (2006.01)
(72) Inventors (Country):
  • SHINGO, TETSURO (Japan)
  • ANDERSEN, LINDA B. (Canada)
  • WEISS, SAMUEL (Canada)
(73) Owners (Country):
  • STEM CELL THERAPEUTICS INC. (Canada)
(71) Applicants (Country):
  • STEM CELL THERAPEUTICS INC. (Canada)
(74) Agent: MARKS & CLERK
(45) Issued:
(86) PCT Filing Date: 2003-07-31
(87) PCT Publication Date: 2004-02-05
Examination requested: 2008-06-03
(30) Availability of licence: N/A
(30) Language of filing: English

(30) Application Priority Data:
Application No. Country Date
60/399,395 United States of America 2002-07-31

View or Download Images

Sorry, the requested images are unavailable. Please try again in a few minutes and contact us  if the problem persists.